Corcept Therapeutics (CORT) Liabilities and Shareholders Equity (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $814.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 3.73% year-over-year to $814.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 billion (up 2.86% YoY), and the FY2025 full-year result was $836.7 million, changed 0.46% from the prior year.
• Liabilities and Shareholders Equity fell to $814.9 million in Q1 2026, from $836.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $846.5 million in Q1 2025 to a low of $468.1 million in Q1 2022.
• A 5-year average of $679.9 million and a median of $655.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 37.68% in 2022, while the deepest fall reached 15.26% in 2022.
• Tracing CORT's Liabilities and Shareholders Equity over 5 years: stood at $583.4 million in 2022, then gained by 6.53% to $621.5 million in 2023, then jumped by 35.24% to $840.6 million in 2024, then retreated by 0.46% to $836.7 million in 2025, then dropped by 2.6% to $814.9 million in 2026.
• Business Quant data shows CORT's Liabilities and Shareholders Equity at $814.9 million in Q1 2026, $836.7 million in Q4 2025, and $823.6 million in Q3 2025.